SG11201810940XA - Methods of treating pancreatic cancer - Google Patents

Methods of treating pancreatic cancer

Info

Publication number
SG11201810940XA
SG11201810940XA SG11201810940XA SG11201810940XA SG11201810940XA SG 11201810940X A SG11201810940X A SG 11201810940XA SG 11201810940X A SG11201810940X A SG 11201810940XA SG 11201810940X A SG11201810940X A SG 11201810940XA SG 11201810940X A SG11201810940X A SG 11201810940XA
Authority
SG
Singapore
Prior art keywords
international
pancreatic cancer
pct
mountain view
maude
Prior art date
Application number
SG11201810940XA
Inventor
Petrus Bekker
Shichang Miao
Israel Charo
Tom Schall
Original Assignee
Chemocentryx Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chemocentryx Inc filed Critical Chemocentryx Inc
Publication of SG11201810940XA publication Critical patent/SG11201810940XA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Abstract

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 21 December 2017 (21.12.2017) WIPO I PCT omit VIII tun Hol VIII HE IN oimIE (10) International Publication Number WO 2017/218544 Al (51) International Patent Classification: A61K 31/18 (2006.01) C07D 417/02 (2006.01) A61K 31/435 (2006.01) CO7D 417/08 (2006.01) A61K 31/43 7 (2006.01) CO7D 471/04 (2006.01) (21) International Application Number: PCT/US2017/037264 (22) International Filing Date: 13 June 2017 (13.06.2017) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 62/349,217 13 June 2016 (13.06.2016) US 62/382,689 01 September 2016 (01.09.2016) US (71) Applicant: CHEMOCENTRYX, INC. [US/US]; 850 Maude Avenue, Mountain View, CA 94043 (US). (72) Inventors: BEKKER, Petrus; 850 Maude Avenue, Moun- tain View, CA 94043 (US). MIAO, Shichang; 832 Arc- turns Circle, Foster City, CA 94404 (US). CHARO, Is- rael; 850 Maude Avenue, Mountain View, CA 94043 (US). SCHALL, Tom; 850 Maude Avenue, Mountain View, CA 94043 (US). (74) Agent: MARSHALL, Ryan, L.; Brinks Gilson & Lione, P.O. Box 10087, Chicago, IL 60610 (US). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Published: with international search report (Art. 21(3)) before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h)) = (54) Title: METHODS OF TREATING PANCREATIC CANCER Figure 1: Mean plasma concentration — Time profile of Compound lb following i.v. dosing in dog of Compound lb 25 Time [hr] rn 1000 100 71' 71' 10 11 )I 1C. 0 5 10 15 20 N el (57) : The present disclosure describes methods of treating pancreatic cancer and limiting over-expression of oncogenes, activating tumor suppressor genes or regulating signaling proteins in patients comprising administering compounds and pharmaceutical 0 combinations as described herein.
SG11201810940XA 2016-06-13 2017-06-13 Methods of treating pancreatic cancer SG11201810940XA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662349217P 2016-06-13 2016-06-13
US201662382689P 2016-09-01 2016-09-01
PCT/US2017/037264 WO2017218544A1 (en) 2016-06-13 2017-06-13 Methods of treating pancreatic cancer

Publications (1)

Publication Number Publication Date
SG11201810940XA true SG11201810940XA (en) 2019-01-30

Family

ID=60663739

Family Applications (2)

Application Number Title Priority Date Filing Date
SG11201810940XA SG11201810940XA (en) 2016-06-13 2017-06-13 Methods of treating pancreatic cancer
SG10202012434QA SG10202012434QA (en) 2016-06-13 2017-06-13 Methods of treating pancreatic cancer

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG10202012434QA SG10202012434QA (en) 2016-06-13 2017-06-13 Methods of treating pancreatic cancer

Country Status (14)

Country Link
EP (1) EP3468548B1 (en)
JP (3) JP7083214B2 (en)
KR (2) KR20230047210A (en)
CN (1) CN109562086A (en)
AU (1) AU2017283491B2 (en)
BR (1) BR112018075660A2 (en)
CA (1) CA3026515A1 (en)
ES (1) ES2895749T3 (en)
IL (1) IL263508B2 (en)
MX (1) MX2018015172A (en)
RU (1) RU2768479C2 (en)
SG (2) SG11201810940XA (en)
WO (1) WO2017218544A1 (en)
ZA (1) ZA201808258B (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10195188B2 (en) 2016-06-13 2019-02-05 Chemocentryx, Inc. Method of treating pancreatic cancer
EP3468548B1 (en) * 2016-06-13 2021-08-04 ChemoCentryx, Inc. Methods of treating pancreatic cancer
WO2020060247A1 (en) * 2018-09-19 2020-03-26 오토텔릭바이오 주식회사 Anticancer composition
WO2022042537A1 (en) * 2020-08-24 2022-03-03 江苏恒瑞医药股份有限公司 APPLICATION OF COMBINATION OF FUSION PROTEIN OF TGF-β RECEPTOR AND MULTI-TARGETED TYROSINE KINASE INHIBITOR IN PREPARING ANTI-TUMOR DRUG
WO2023040804A1 (en) * 2021-09-14 2023-03-23 信达生物制药(苏州)有限公司 Pharmaceutical composition of anti-pd-1 antibody and chemotherapy agent and method for using same
CN115521913B (en) * 2022-02-22 2023-07-25 北京景达生物科技有限公司 NK cells and CD20, CD38 and Her2 antibodies combined application
CN116804221B (en) * 2023-08-23 2023-11-03 汲迈生命科技(苏州)有限公司 Application of LMO7 expression level in prediction of pancreatic cancer gemcitabine resistance

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS52010B (en) * 2005-06-22 2012-04-30 Plexxikon Inc. Pyrrolo [2, 3-b]pyridine derivatives as protein kinase inhibitors
US8519135B2 (en) * 2006-07-14 2013-08-27 Chemocentryx, Inc. Heteroaryl sulfonamides and CCR2/CCR9
EP2099454A4 (en) * 2006-11-17 2010-11-10 Abbott Lab Aminopyrrolidines as chemokine receptor antagonists
US7776877B2 (en) * 2007-06-22 2010-08-17 Chemocentryx, Inc. N-(2-(hetaryl)aryl) arylsulfonamides and N-(2-(hetaryl) hetaryl arylsulfonamides
PL2175859T3 (en) * 2007-07-12 2012-09-28 Chemocentryx Inc Fused heteroaryl pyridyl and phenyl benzenesulfonamides as ccr2 modulators for the treament of inflammation
CA2709806A1 (en) * 2008-01-22 2009-07-30 Merck Patent Gmbh Protein kinase inhibitors and use thereof
TW201041888A (en) * 2009-05-06 2010-12-01 Plexxikon Inc Compounds and methods for kinase modulation, and indications therefor
MX2012006964A (en) * 2009-12-17 2012-07-17 Boehringer Ingelheim Int New ccr2 receptor antagonists and uses thereof.
US8916601B2 (en) * 2012-02-29 2014-12-23 Chemocentryx, Inc. Aza-aryl 1H-pyrazol-1-YL benzene sulfonamides
US10189777B2 (en) * 2014-05-05 2019-01-29 Lycera Corporation Benzenesulfonamido and related compounds for use as agonists of RORγ and the treatment of disease
EP3468548B1 (en) 2016-06-13 2021-08-04 ChemoCentryx, Inc. Methods of treating pancreatic cancer

Also Published As

Publication number Publication date
ES2895749T3 (en) 2022-02-22
WO2017218544A1 (en) 2017-12-21
IL263508A (en) 2019-01-31
ZA201808258B (en) 2022-04-28
JP2019518038A (en) 2019-06-27
BR112018075660A2 (en) 2019-04-09
RU2019100220A3 (en) 2020-12-24
KR20230047210A (en) 2023-04-06
AU2017283491B2 (en) 2021-06-03
EP3468548A1 (en) 2019-04-17
MX2018015172A (en) 2019-07-04
IL263508B2 (en) 2023-06-01
AU2017283491A1 (en) 2018-12-20
CA3026515A1 (en) 2017-12-21
EP3468548B1 (en) 2021-08-04
JP2020147602A (en) 2020-09-17
KR20190017913A (en) 2019-02-20
JP7083214B2 (en) 2022-06-10
JP2020147601A (en) 2020-09-17
EP3468548A4 (en) 2020-01-22
SG10202012434QA (en) 2021-01-28
RU2019100220A (en) 2020-07-15
RU2768479C2 (en) 2022-03-24
CN109562086A (en) 2019-04-02

Similar Documents

Publication Publication Date Title
SG11201810940XA (en) Methods of treating pancreatic cancer
SG11201909955XA (en) Formulations of anti-lag3 antibodies and co-formulations of anti-lag3 antibodies and anti-pd-1 antibodies
SG11201805044WA (en) Compounds useful as kinase inhibitors
SG11201809912UA (en) Hybrid carriers for nucleic acid cargo
SG11201811432WA (en) Rna for cancer therapy
SG11201804373VA (en) Compositions and methods for immunooncology
SG11201806863WA (en) Tetracyclic pyridone compounds as antivirals
SG11201804901WA (en) Compounds for the treatment of cancer and inflammatory disease
SG11201808622SA (en) Chimeric receptors to flt3 and methods of use thereof
SG11201808125RA (en) Methods for solid tumor treatment
SG11201908598PA (en) Compounds useful in the treatment or prevention of a prmt5-mediated disorder
SG11201900163PA (en) Macrocycle kinase inhibitors
SG11201808237UA (en) Substituted indole compound derivatives as dengue viral replication inhibitors
SG11201908786VA (en) Substituted indoline derivatives as dengue viral replication inhibitors
SG11201805072PA (en) Nicotine powder delivery system
SG11201808222RA (en) Methods of treatment of cholestatic diseases
SG11201908602UA (en) Combination therapy for the treatment of solid and hematological cancers
SG11201908465QA (en) Substituted indoline derivatives as dengue viral replication inhibitors
SG11201804263PA (en) Cancer treatment using 2-deoxy-2-fluoro-l-fucose in combination with a checkpoint inhibitor
SG11201808138YA (en) Substituted indole derivatives as dengue viral replication inhibitors
SG11201906436VA (en) Novel heterocyclic compound, its preparation method, and pharmaceutical composition comprising the same
SG11201804704PA (en) Compositions and methods for decreasing tau expression
SG11201901534VA (en) Combination therapy with controlled-release cnp agonists
SG11201902531QA (en) Liquid pharmaceutical composition
SG11201810333UA (en) Combination of anti-cd20 antibody, p13 kinase-delta selective inhibitor, and btk inhibitor to treat b-cell proliferative disorders